Recordati Rare Diseases

Recordati Rare Diseases Canada Inc. is part of the Recordati Group, established in Italy in 1926. The group researches and develops treatments for rare diseases and medicines mainly for cardiovascular and urogenital disorders.

Recordati manufactures and supplies its active pharmaceutical ingredient portfolio to customers worldwide. Its active principles cover therapeutic areas in primary and specialty care.

Since 2007, Recordati Rare Diseases has focused on people with little-known conditions. Its mission is to reduce the impact of rare diseases by providing urgently needed medicines.

Recordati provides medicines across therapeutic areas and says people with rare diseases have the right to treatment.

Recordati seeks candidates across its business units and does not accept referrals from employment businesses or agencies for vacancies posted on its site.

Recordati began as a family-run pharmacy in Correggio, Italy, in the 1920s and has more than 4,300 employees. The company describes its work as focused on medicines.

The page lists executives and regional or functional leaders, including Scott Pescatore, Mohamed Ladha, Bruno Parenti, Luigi Longinotti, Aziza Johnson, Davide Paganoni and Elisabeth Bergmans.

Recordati describes its community as united by a passion for unlocking life’s potential and says its patient-focused culture dates to its beginnings in an Italian pharmacy in 1926.

In the 19th century the Recordati family began a small pharmacy, in Correggio, Northern Italy, serving their local community. In 1926, Giovanni Recordati moves from experimenting in the back of that same pharmacy, to founding a company at 28 years old “Laboratorio Farmacologico Reggiano”.

Recordati operates across specialty and primary care, consumer healthcare, and rare diseases. Its integrated operations span research and development, chemical and finished-product manufacturing, commercialisation and licensing.

Recordati Rare Diseases is a business unit focused on rare diseases within the Recordati Group, which has delivered medicines for 100 years. The group’s purpose is to unlock the full potential of life.

The page provides remuneration reports and policy documents, including reports on the 2023 policy and remuneration paid for 2022, and reports for earlier years.

Recordati Rare Diseases’ pharmacovigilance work aims to support patient care and safety and provides information for assessing the risk-benefit profile of medicines.

Recordati is headquartered in Milan, Italy, and has worldwide operations and strategic partnerships. The page lists approximately 150 countries, seven production plants and more than 4,300 employees.

Since 2007, Recordati Rare Diseases has focused on people with little-known conditions and aims to reduce the impact of rare diseases by providing urgently needed medicines in key therapeutic areas.